MohammadRazaqMD

Oncology • Oklahoma City, OK

Assistant Professor, Medicine, University of Oklahoma College of Medicine

Join to view full profile

Dr. Razaq is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Razaq's full profile

Already have an account?

Office
800 NE 10th St
Oklahoma City, OK 73104
Phone+1 405-271-4022

Fax+1 405-271-4221

Education & Training

NYC Health & Hospitals/South Brooklyn HealthFellowship, Hematology, 2003 - 2004
NYC Health & Hospitals/South Brooklyn HealthResidency, Internal Medicine, 2000 - 2003
King Edward Medical UniversityClass of 1997

Certifications & Licensure

OK State Medical License 2012 - 2025
KS State Medical License 2010 - 2013
NE State Medical License 2010 - 2012
IA State Medical License 2008 - 2011
NY State Medical License 2004 - 2009
IL State Medical License 2002 - 2005
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
ACTIVE_NOT_RECRUITING
PHASE3
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2012 Sep 28
Completed
Phase 1, Phase 2
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) Start of enrollment: 2015 Feb 11
ACTIVE_NOT_RECRUITING
PHASE3
OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure Start of enrollment: 2016 Feb 12
Terminated
Phase 3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

75 citations
Phase 1/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma.
David Cognetti, Jennifer Johnson, Joseph Curry, Samith T. Kochuparambil, Darren McDonald
Head & Neck. 2021-10-09
1 citations
Merkel cell carcinoma: treatment and outcomes over a 10-year period at a high-volume academic center.
My-Lien Nguyen, Ana Mohammad-Zadeh, Greg A. Krempl, Mohammad Razaq, Lindsey Collins
International Journal of Dermatology. 2021-07-20
292 citations
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a rando...
Nancy Y. Lee, Robert L. Ferris, Amanda Psyrri, Robert I. Haddad, Makoto Tahara
The Lancet. Oncology. 2021-04-01

Press Mentions

OncLive® Presents State of the Science Summit™ on Non-Small Cell Lung CancerJune 12th, 2019